London-based health tech startup Bioniq, known for creating personalized supplements based on blood biomarker data, has successfully closed a €13.7 million ($15 million) Series B funding round. This round, led by HV Capital and Unbound, brings Bioniq’s valuation to €68.73 million ($75 million).
The firm’s innovative approach leverages AI to provide highly personalized supplements tailored to individual nutritional needs. CEO and co-founder Vadim Fedotov emphasized the importance of this funding: “We’ve entered a new era in nutritional supplementation where one-size-fits-all solutions are inefficient. Our AI-driven approach allows us to create customized supplements that provide quantifiable results and cater to individuals’ specific needs.”
Advertisement
Strategic Growth and Market Expansion
The fresh capital will be used to expand the global market share, focusing on product development, integrating a global laboratory network, and enhancing operations in the US and the Middle East. The company aims to disrupt the dietary supplements market with its advanced, personalized health optimization solutions.
Key Offerings and Technology
Launched in 2019, the company offers two primary products: Bioniq PRO and Bioniq GO. Bioniq PRO uses blood biomarker data to create tailored daily supplements, including consultations with a registered dietitian. Bioniq GO, a more accessible option, uses a questionnaire and AI algorithms to recommend supplement blends based on extensive biochemical data.
Thiur Swiss-made, pharmaceutical-grade supplements feature precise micro-dosing and are delivered in patented prebiotic guar granules, enhancing nutrient absorption.
Impressive Growth and Industry Impact
Bioniq has seen significant growth, particularly in the US, which now accounts for over 50% of its customer base. The company’s data-driven approach and partnerships with leading health and sports institutions have made it a preferred choice for top athletes and wellness centers.
David Kuczek, General Partner at HV Capital, praised the company’s growth: “Bioniq’s exceptional growth is a testament to its innovative approach to high-quality personalized health solutions that professional athletes worldwide rely on.”
Shravin Mittal, CEO of Unbound, added, “We are impressed by the vision and technology. They are disrupting the supplement industry with their personalized and science-based approach. We are excited to support their growth and scale their business.”
With this significant investment, the UK-based startup is set to further enhance its AI-driven supplement solutions and expand its global presence, transforming the personalized nutrition market.
